ArticleFrontiers in oncology2026
A novel short-term outcome prediction model for esophagectomy patients receiving neoadjuvant immunochemotherapy and neoadjuvant chemotherapy: a muti-center retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Due to the lack of a comprehensive evaluation of the short-term prognosis of patients undergoing radical resection of esophageal cancer after neoadjuvant therapy, recent clinical strategies have remained subjective and controversial. The recognition of pretreatment risk factors and tailored treatment could improve outcomes of esophagectomy patients. Therefore, we aimed to develop a predictive model that differentiates high-risk conditions after surgery in patients with esophageal cancer receiving neoadjuvant therapy. Methods: We conducted a muti-center, retrospective cohort study in Fujian Medical University Union Hospital, Ganzhou Cancer Hospital and Affiliated Hospital of Jinggangshan University. A principal component (PC) analysis was applied for data simplification and the extraction of patient short-term outcome characteristic. We identified risk status on admission and operation, via a logistic regression and then constructed prediction models for worsened short-term outcomes. Results: Of 334 patients of train set underwent neoadjuvant therapy and esophagectomy, 142(42.5%) received neoadjuvant chemotherapy (NC), 192(57.5%) received neoadjuvant immunochemotherapy (NIC). After grouping by principal component analysis, patients were divided into high-risk group (83,25%) and low-risk group (251,75%). Twelve features regarding clinical feature, nutrition indicators, laboratory indicators and intraoperative data were identified. The prediction model showed the best performance in predicting high short-term outcome risk, with an area under the receiver operating characteristic curve (AUC) of 0.794 (95%CI, 0.712,0.876) in NC, and 0.781 (95%CI, 0.705,0.858) in NIC. Conclusion: A novel short-term outcome prediction model, offers a comprehensive assessment of posttreatment recovery in esophagectomy patients after neoadjuvant immunotherapy combined with chemotherapy and neoadjuvant chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.